Biosimilars: Opportunities and Challenges for Nurse Practitioners

被引：2

作者：

Rumore, Martha M. ^{[1
]}

Cobb, Elizabeth ^{[2
]}

Sullivan, Maureen ^{[3
]}

Wittman, Deborah ^{[4
,5
]}

机构：

[1] Sorrell Lenna & Schmidt LLP, Touro Coll Pharm & Counsel, New York, NY USA

[2] Mt Sinai Beth Israel, Pharm, New York, NY USA

[3] Touro Coll Pharm, Dept Pharm Practice, New York, NY USA

[4] Touro Coll Pharm, New York, NY USA

[5] Mt Sinai St Lukes Hosp, New York, NY USA

来源：

JNP-JOURNAL FOR NURSE PRACTITIONERS | 2016年 / 12卷 / 03期

关键词：

biosimilar; biologic; biologics; Food and Drug Administration; interchangeability; substitution; COMPARABILITY; SAFETY;

D O I：

10.1016/j.nurpra.2015.08.027

中图分类号：

R47 [护理学];

学科分类号：

1011 ;

摘要：

The science, regulatory, and pharmacovigilance processes for biosimilars are evolving. The Biologics Price Competition and Innovation Act created an abridged approval pathway for biosimilars. The first biosimilar was Food and Drug Administration approved in 2015 with others currently pending approval. As biosimilars become marketed, nurse practitioners will be faced with many challenges, including patient questions regarding them. Nurse practitioners have an important role in the identification of possible safety profile differences between biosimilars and innovator biologicals, especially for immunogenicity. A number of practical considerations need to be addressed including substitutability; off-label prescribing; patient-specific record keeping; and computerized prescriber order entry, education, and reimbursement. (C) 2016 Elsevier, Inc. All rights reserved.

引用

页码：181 / 191

页数：11

共 50 条

[1] Opportunities and challenges with biosimilars - Introduction
Tesar, Vladimir
[J]. KIDNEY & BLOOD PRESSURE RESEARCH, 2007, 30 : 1 - 1
[2] Biosimilars as antivirals: opportunities and challenges
Jarab, Anan S.
Abu Heshmeh, Shrouq R.
Al Meslamani, Ahmad Z.
[J]. EXPERT REVIEW OF ANTI-INFECTIVE THERAPY, 2024, 22 (05) : 273 - 275
[3] Opportunities and challenges of extrapolation for biosimilars
Weise, M.
Wolff-Holz, E.
[J]. ZEITSCHRIFT FUR GASTROENTEROLOGIE, 2016, 54 (11): : 1211 - 1216
[4] Leadership Opportunities for Nurse Practitioners
Ferrara, Stephen A.
[J]. JNP- THE JOURNAL FOR NURSE PRACTITIONERS, 2024, 20 (06):
[5] Biosimilars production in Africa opportunities & challenges
Abdel-Maged, Amany E.
Mikhaeil, Margrit F.
Elkordy, Ahmed I.
Gad, Amany M.
Elshazly, Mohamed M.
[J]. REGULATORY TOXICOLOGY AND PHARMACOLOGY, 2024, 149
[6] Challenges and Opportunities for Biosimilars Developers in the US
Ritter, Amy
Barry, Nora
[J]. BIOPHARM INTERNATIONAL, 2012, 25 (09) : 24 - 25
[7] Emerging biosimilars market presents opportunities and challenges
de Lartigue, Jane
[J]. JOURNAL OF COMMUNITY AND SUPPORTIVE ONCOLOGY, 2018, 16 (06): : E283 - E289
[8] The Expanding Role of Nurse Practitioners in Home-Based Primary Care Opportunities and Challenges
Wolff-Baker, Deborah
Ordona, Ron Billano
[J]. JOURNAL OF GERONTOLOGICAL NURSING, 2019, 45 (06): : 9 - 14
[9] Emerging Opportunities and Challenges of Biosimilars in Oncology Practice
Lyman, Gary H.
[J]. JOURNAL OF ONCOLOGY PRACTICE, 2017, 13 (09) : 7S - +
[10] Retrieval Nurse Practitioners: The role and the challenges
Herring, Sasha
[J]. AUSTRALIAN CRITICAL CARE, 2013, 26 (03) : 102 - 103

← 1 2 3 4 5 →